Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Tumor Immunotherapy01:27

Tumor Immunotherapy

498
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
498
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Free-floating long-term vascularized mesenchymal organoids.

iScience·2026
Same author

iMer, a naturally occurring MERTK splice variant, binds to GAS6 to decrease platelet activation and thrombus formation.

Blood vessels, thrombosis & hemostasis·2025
Same author

Prospects of current AXL-targeting therapies in early phase cancer trials.

Expert opinion on investigational drugs·2025
Same author

Identification of leukemia-enriched signature through the development of a comprehensive pediatric single-cell atlas.

Nature communications·2025
Same author

Discovery of Novel TYRO3/MERTK Dual Inhibitors.

Journal of medicinal chemistry·2025
Same author

Exploiting structural variability in the kinase back-pocket to modulate polypharmacology of TAM inhibitors.

European journal of medicinal chemistry·2025

Related Experiment Video

Updated: Jun 19, 2025

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells
09:37

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells

Published on: August 25, 2021

1.8K

MERTK Inhibition as a Targeted Novel Cancer Therapy.

K M Tanim1,2, Alisha Holtzhausen3, Aashis Thapa1,2

  • 1Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA 30322, USA.

International Journal of Molecular Sciences
|July 27, 2024
PubMed
Summary
This summary is machine-generated.

This review highlights the 30-year journey of TYRO3, AXL, and MERTK (TAM) receptor tyrosine kinases. Understanding their roles in cancer and autoimmunity is advancing, paving the way for new therapies.

Keywords:
MERTKMERTK InhibitorsTAMreceptor tyrosine kinasetargeted cancer therapy

More Related Videos

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.0K
Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

7.6K

Related Experiment Videos

Last Updated: Jun 19, 2025

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells
09:37

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells

Published on: August 25, 2021

1.8K
Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.0K
Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

7.6K

Area of Science:

  • Molecular biology
  • Biochemistry
  • Immunology

Background:

  • The TYRO3, AXL, and MERTK (TAM) family of receptor tyrosine kinases (RTKs) were discovered as orphan RTKs with unknown functions.
  • Their roles in physiology and pathophysiology have become clearer in the last decade.
  • Ligand activation via externalized phosphatidylserine (PtdSer) links TAM RTKs to diverse processes.

Purpose of the Study:

  • To review the discovery, signaling, and clinical potential of MERTK (c-mer).
  • To highlight progress in understanding TAM RTK family functions over 30 years through Earp and Graham lab collaborations.
  • To set the stage for future research and therapeutic interventions.

Main Methods:

  • Review of scientific literature and research findings.
  • Focus on the collaborative work of the Earp and Graham labs.
  • Analysis of the historical progression of TAM RTK research.

Main Results:

  • TAM RTKs, including MERTK, are involved in crucial biological processes.
  • Externalized phosphatidylserine (PtdSer) is a key activator for TAM RTKs.
  • These kinases play roles in neurodevelopment, cancer, and autoimmunity.

Conclusions:

  • The TAM RTK field has significantly advanced, moving beyond orphan status.
  • Further research into TAM RTK signaling is crucial for therapeutic development.
  • Understanding MERTK and related kinases offers potential for treating various diseases.